Immunic, Inc. (NASDAQ:IMUX) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Immunic, Inc. (NASDAQ:IMUX) have received a consensus rating of “Moderate Buy” from the nine brokerages that are currently covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have issued a buy recommendation and two have given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $5.6429.

Several research firms recently weighed in on IMUX. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a report on Monday, December 29th. Stifel Nicolaus set a $2.50 price objective on Immunic in a report on Thursday. Guggenheim began coverage on Immunic in a report on Tuesday, March 24th. They issued a “buy” rating and a $7.00 price objective for the company. D. Boral Capital downgraded Immunic from a “buy” rating to a “hold” rating in a report on Wednesday. Finally, upgraded Immunic to a “strong-buy” rating in a report on Tuesday, February 3rd.

Immunic Price Performance

IMUX stock opened at $1.00 on Friday. The business has a 50-day moving average price of $1.08 and a 200 day moving average price of $0.84. The company has a market capitalization of $130.46 million, a P/E ratio of -1.43 and a beta of 1.37. Immunic has a 1-year low of $0.51 and a 1-year high of $1.51.

Immunic’s stock is going to reverse split on the morning of Monday, April 27th. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, April 26th.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Thursday, February 26th. The company reported ($0.12) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.02). On average, analysts anticipate that Immunic will post -0.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Immunic

A number of large investors have recently added to or reduced their stakes in IMUX. Nantahala Capital Management LLC bought a new position in Immunic in the fourth quarter worth about $2,337,000. Millennium Management LLC raised its holdings in Immunic by 544.6% in the fourth quarter. Millennium Management LLC now owns 3,419,299 shares of the company’s stock worth $1,825,000 after purchasing an additional 2,888,829 shares in the last quarter. Laurion Capital Management LP raised its holdings in Immunic by 106.3% in the fourth quarter. Laurion Capital Management LP now owns 3,882,162 shares of the company’s stock worth $2,072,000 after purchasing an additional 2,000,000 shares in the last quarter. Marshall Wace LLP raised its holdings in Immunic by 91.2% in the fourth quarter. Marshall Wace LLP now owns 1,019,983 shares of the company’s stock worth $541,000 after purchasing an additional 486,468 shares in the last quarter. Finally, Connective Capital Management LLC bought a new position in Immunic in the fourth quarter worth about $161,000. 51.82% of the stock is currently owned by institutional investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.